Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 2/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4480762 | 1.00 | GABRR1 (0.33) | GABRR1GABRR2BLMGABRR3LMNA | |
| SCHEMBL4483910 | 1.00 | GABRR1 (0.33) | GABRR1GABRR2BLMGABRR3LMNA | |
| SCHEMBL1937866 | 0.90 | DUT (0.35) | GABRR1GABRR2BLMGABRR3LMNA | |
| SCHEMBL1937865 | 0.90 | DUT (0.35) | GABRR1GABRR2BLMGABRR3LMNA | |
| SCHEMBL1930406 | 0.87 | TBXAS1 (0.38) | BLMAPEX1HCAR2DUTTBXAS1 | |
| SCHEMBL1930407 | 0.87 | TBXAS1 (0.38) | BLMAPEX1HCAR2DUTTBXAS1 | |
| SCHEMBL1011244 | 0.87 | TBXAS1 (0.38) | BLMAPEX1HCAR2DUTTBXAS1 | |
| SCHEMBL1151126 | 0.87 | TBXAS1 (0.38) | BLMAPEX1HCAR2DUTTBXAS1 | |
| SCHEMBL8798894 | 0.87 | TBXAS1 (0.38) | BLMAPEX1HCAR2DUTTBXAS1 | |
| SCHEMBL3448750 | 0.83 | HCAR2 (0.39) | HCAR2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3766878-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| EP-3766878-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3307729-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-09-02 | — | — | EP | disclosed |
| US-20190224212-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-07-25 | — | — | US | disclosed |
| US-10272095-B2 | NRF2 regulators | GlaxoSmithKline Intellectual Propert Development Limited (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20180169110-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| WO-2018104766-A1 | 3-(2,3-DIHYDRO-1H-INDEN-5-YL)PROPANOIC ACID DERIVATIVES AND THEIR USE AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-14 | — | — | WO | disclosed |
| EP-3307729-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016203401-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
| US-7507854-B2 | Impurity reduction in Olefin metathesis reactions | MATERIA, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20050203324-A1 | Impurity reduction in Olefin metathesis reactions | MATERIA, INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272095-B2 | NRF2 regulators | NFE2L2, KEAP1, NQO1 | GABRR1 1463/4885GABRR2 1233/4885BLM 1586/4885 |
| US-20190224212-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | GABRR1 1463/4885GABRR2 1233/4885BLM 1586/4885 |
| US-20180169110-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | GABRR1 1463/4885GABRR2 1233/4885BLM 1586/4885 |
| US-20050203324-A1 | Impurity reduction in Olefin metathesis reactions | CYP51A1, COASY, ECI1 | GABRR1 969/4885GABRR2 1227/4885BLM 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.